SQX-logo
SQXlogo
  • My Dashboard
  • Bond Academy
  • Tools
    • Bond Screener
    • Issuer Directory
    • Portfolio Builder
    • Discussion Board
  • Data Partners
‌
‌
  • Home
  • My Dashboard
  • Bond Academy
  • Tools
  • Data Partners
  • LoginCreate a free account
SQX-logo
SQX-white-logo© SQX BONDS. All rights reserved | Privacy Policy | Terms and Conditions | Represent a financial institution? | Customer Support
Visit SQXBonds on linkedinVisit SQXBonds on LinkedInVisit SQXBonds on facebookVisit SQXBonds on LinkedInVisit SQXBonds on instagramVisit SQXBonds on LinkedInVisit SQXBonds on twitterVisit SQXBonds on LinkedInVisit SQXBonds on iplVisit SQXBonds on LinkedIn
  1. Screener
  2. Issuers index
  3. F
  4. Fred Hutchinson Cancer Research Center

Fred Hutchinson Cancer Research Center Bonds

Fred Hutchinson Cancer Research Center, founded in 1975 and located in Seattle, Washington, is a world-renowned nonprofit organization dedicated to cancer research and treatment. The center is operationally focused on pioneering innovative science that leads to advances in cancer treatment, prevention, and understanding the disease through its multifaceted research programs and clinical trials.

Bond NameCountryMaturityCoupon(%)
FHUTCH 3.95% 2050-01-01 USDFred Hutchinson Cancer Research CenterUnited States2050-01-013.9495.74
FHUTCH 4.97% 2052-01-01 USDFred Hutchinson Cancer Research CenterUnited States2052-01-014.9665.44
Showing results 1 - 2 of 2
Per page

Company overview and issue history are AI generated, and should not be cited or relied on without verification.

Fred Hutchinson Cancer Research Center issue history

Since its inception, Fred Hutch has issued bonds to support its research initiatives, including a notable $100 million bond issuance in 2015 aimed at funding new research facilities. The center's bonds typically offer competitive yields compared to the healthcare sector, reflecting strong demand for its critical research efforts. Recently, Fred Hutch announced plans to issue additional bonds to expand its immunotherapy programs, further solidifying its commitment to cutting-edge cancer treatments and research advancements.